Logo image of CLPT

CLEARPOINT NEURO INC (CLPT) Stock Fundamental Analysis

NASDAQ:CLPT - Nasdaq - US18507C1036 - Common Stock - Currency: USD

12.83  -0.35 (-2.66%)

Fundamental Rating

4

Taking everything into account, CLPT scores 4 out of 10 in our fundamental rating. CLPT was compared to 189 industry peers in the Health Care Equipment & Supplies industry. CLPT has a great financial health rating, but its profitability evaluates not so good. CLPT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year CLPT has reported negative net income.
CLPT had a negative operating cash flow in the past year.
In the past 5 years CLPT always reported negative net income.
In the past 5 years CLPT always reported negative operating cash flow.
CLPT Yearly Net Income VS EBIT VS OCF VS FCFCLPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

CLPT's Return On Assets of -48.26% is on the low side compared to the rest of the industry. CLPT is outperformed by 66.14% of its industry peers.
CLPT's Return On Equity of -74.50% is in line compared to the rest of the industry. CLPT outperforms 41.80% of its industry peers.
Industry RankSector Rank
ROA -48.26%
ROE -74.5%
ROIC N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
CLPT Yearly ROA, ROE, ROICCLPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CLPT has a better Gross Margin (60.92%) than 60.85% of its industry peers.
CLPT's Gross Margin has declined in the last couple of years.
CLPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
CLPT Yearly Profit, Operating, Gross MarginsCLPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

7

2. Health

2.1 Basic Checks

CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLPT has more shares outstanding
CLPT has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CLPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLPT Yearly Shares OutstandingCLPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CLPT Yearly Total Debt VS Total AssetsCLPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 9.04 indicates that CLPT is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.04, CLPT belongs to the top of the industry, outperforming 89.42% of the companies in the same industry.
There is no outstanding debt for CLPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.04
ROIC/WACCN/A
WACC9.05%
CLPT Yearly LT Debt VS Equity VS FCFCLPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

CLPT has a Current Ratio of 3.22. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.22, CLPT perfoms like the industry average, outperforming 55.56% of the companies in the same industry.
A Quick Ratio of 2.56 indicates that CLPT has no problem at all paying its short term obligations.
CLPT's Quick ratio of 2.56 is in line compared to the rest of the industry. CLPT outperforms 58.73% of its industry peers.
Industry RankSector Rank
Current Ratio 3.22
Quick Ratio 2.56
CLPT Yearly Current Assets VS Current LiabilitesCLPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

7

3. Growth

3.1 Past

CLPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.52%, which is quite good.
CLPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 31.04%.
The Revenue has been growing by 22.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.5%
Revenue 1Y (TTM)31.04%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%11.07%

3.2 Future

The Earnings Per Share is expected to grow by 3.12% on average over the next years.
The Revenue is expected to grow by 32.35% on average over the next years. This is a very strong growth
EPS Next Y-11.71%
EPS Next 2Y1.42%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue Next Year21.77%
Revenue Next 2Y27.72%
Revenue Next 3Y32.35%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLPT Yearly Revenue VS EstimatesCLPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 2031 2032 50M 100M 150M 200M
CLPT Yearly EPS VS EstimatesCLPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLPT. In the last year negative earnings were reported.
Also next year CLPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLPT Price Earnings VS Forward Price EarningsCLPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLPT Per share dataCLPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.42%
EPS Next 3Y3.12%

0

5. Dividend

5.1 Amount

No dividends for CLPT!.
Industry RankSector Rank
Dividend Yield N/A

CLEARPOINT NEURO INC

NASDAQ:CLPT (5/19/2025, 11:24:09 AM)

12.83

-0.35 (-2.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-05 2025-08-05
Inst Owners33.28%
Inst Owner Change3.85%
Ins Owners4.61%
Ins Owner Change10.25%
Market Cap358.98M
Analysts84.44
Price Target28.22 (119.95%)
Short Float %4.15%
Short Ratio4.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.93%
Min EPS beat(2)-20.05%
Max EPS beat(2)-1.81%
EPS beat(4)2
Avg EPS beat(4)3.95%
Min EPS beat(4)-20.05%
Max EPS beat(4)20.24%
EPS beat(8)4
Avg EPS beat(8)-3.22%
EPS beat(12)8
Avg EPS beat(12)2.38%
EPS beat(16)9
Avg EPS beat(16)0.23%
Revenue beat(2)1
Avg Revenue beat(2)-2.53%
Min Revenue beat(2)-7.42%
Max Revenue beat(2)2.36%
Revenue beat(4)3
Avg Revenue beat(4)1.78%
Min Revenue beat(4)-7.42%
Max Revenue beat(4)7.08%
Revenue beat(8)5
Avg Revenue beat(8)-0.44%
Revenue beat(12)7
Avg Revenue beat(12)0.48%
Revenue beat(16)9
Avg Revenue beat(16)1.67%
PT rev (1m)10.67%
PT rev (3m)23.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-21.05%
EPS NY rev (3m)-30.68%
Revenue NQ rev (1m)3.14%
Revenue NQ rev (3m)-3.61%
Revenue NY rev (1m)2.02%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.44
P/FCF N/A
P/OCF N/A
P/B 14.14
P/tB 14.41
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.33
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS1.12
BVpS0.91
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.26%
ROE -74.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.92%
FCFM N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
F-Score5
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.06%
Cap/Sales 0.88%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.22
Quick Ratio 2.56
Altman-Z 9.04
F-Score5
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)185.37%
Cap/Sales(3y)3.62%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-37.5%
EPS Next Y-11.71%
EPS Next 2Y1.42%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue 1Y (TTM)31.04%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%11.07%
Revenue Next Year21.77%
Revenue Next 2Y27.72%
Revenue Next 3Y32.35%
Revenue Next 5YN/A
EBIT growth 1Y12.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.8%
EBIT Next 3Y25.55%
EBIT Next 5YN/A
FCF growth 1Y37.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.77%
OCF growth 3YN/A
OCF growth 5YN/A